Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Representative image: Preclinical cardiovascular research and lab-based epigenetic drug development, relevant to CS014's antithrombotic profile without bleeding risk
Pharma & Biotech

Cereno Scientific’s CS014 shows antithrombotic effect without bleeding risk in new HDAC study

Cereno Scientific has announced the peer-reviewed publication of its next-generation HDAC inhibitor CS014 in the Journal of Thrombosis and Haemostasis, revealing the compound’s ability to significantly reduce thrombosis without increasing bleeding risk. The study marks the first formal disclosure of CS014’s chemical structure and nonclinical pharmacology, positioning the compound as a differentiated HDAC inhibitor with

Read More
Pharma & Biotech

How annamycin’s clean cardiac safety profile may strengthen Moleculin’s oncology development strategy

Independent reviewers found no cardiotoxicity for Moleculin’s annamycin in 90 subjects. See how this safety milestone may reshape its oncology development path.

Read More
Pharma & Biotech

Why Creative Medical Technology Holdings’ ADAPT interim results may mark a turning point for cell-based chronic pain treatments

Find out how positive interim ADAPT trial data for CELZ-201 may signal a turning point in regenerative, non-opioid treatment approaches for chronic lower back pain.

Read More
Representative image showing cardiac monitoring and medication, relevant to Thryv Therapeutics’ Wave II trial of THRV-1268 for Long QT Syndrome Type 2 (LQTS2), where SGK1 inhibition aims to directly address QT prolongation.
Pharma & Biotech

Can Thryv’s SGK1 inhibitor become the first disease-modifying therapy for long QT syndrome type 2?

Thryv Therapeutics Inc. has initiated its pivotal Phase 2/3 Wave II clinical trial for THRV-1268, a novel orally administered SGK1 inhibitor, in adult patients with Long QT Syndrome Type 2 (LQTS2). The launch builds on promising results from the earlier Wave I study and a subsequent clinical investigation, both of which demonstrated meaningful QT interval

Read More
Pharma & Biotech

Bionpharma wins FDA approval for Etravirine as STEERLife’s FragMelt proves regulatory-ready

Bionpharma Inc. has secured Abbreviated New Drug Application (ANDA) approval from the United States Food and Drug Administration for its generic version of Etravirine tablets, a second-line treatment for HIV-1. Developed in partnership with STEERLife, the formulation leverages the proprietary FragMelt continuous manufacturing platform to overcome the heat- and shear-sensitivity of the active pharmaceutical ingredient.

Read More
Pharma & Biotech

Can ABCL635 redefine non-hormonal menopause treatment? Inside AbCellera’s Phase 2 push

AbCellera advances ABCL635 into Phase 2 for hot flashes. Find out what this means for non-hormonal menopause care and the biotech’s GPCR strategy.

Read More
Representative image of a knee joint affected by tenosynovial giant cell tumor (TGCT), the rare condition targeted by pimicotinib, now under FDA review for potential approval as a first-in-class oral CSF-1R inhibitor.
Pharma & Biotech

FDA accepts pimicotinib NDA for TGCT: What this signals for rare tumor drug development and the CSF-1R inhibitor class

Find out how Abbisko’s TGCT drug pimicotinib just crossed a major milestone with the FDA—and what this means for patients and the CSF-1R class.

Read More
Pharma & Biotech

Is insitro’s TherML platform finally delivering on the AI-native promise for biologics and small molecules?

insitro has announced the acquisition of CombinAbleAI and launched its new TherML platform, a modality-agnostic, AI-powered system that integrates small molecules, oligonucleotides, and biologics into a unified therapeutic design stack. The move signals a strategic attempt to industrialize AI-native drug discovery across modalities while reducing late-stage attrition risks. What makes this acquisition different from typical

Read More
Pharma & Biotech

Why Oncolytics Biotech’s new GOBLET cohort 4 data matters for third-line anal cancer immunotherapy strategies

Find out why Oncolytics Biotech’s latest GOBLET cohort 4 data could reshape immunotherapy strategies for third-line anal cancer.

Read More
Pharma & Biotech

A rare survival signal in pancreatic cancer? Actuate Therapeutics’ elraglusib data at ASCO GI 2026 reignites first-line treatment hopes

Find out how Actuate Therapeutics’ elraglusib Phase 2 data at ASCO GI 2026 could change first-line treatment strategies for metastatic pancreatic cancer.

Read More